Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Revolution Medicines, Inc.RVMD · Entity 606 | Chief Financial Officer | September 16, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Revolution Medicines, Inc.
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 123,208 |
Reported balance
After 2026-09-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-16 · Sale · Disposed 61 · Balance 123,208 F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. |
| Common StockSEC Table I · non-derivative | Direct | 119,216 |
Reported balance
After 2026-09-16 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-16 · Sale · Disposed 3,992 · Balance 119,216 F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F2: Includes 43,650 restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.
F2: Includes 43,650 restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2026 Filed Sep 18, 2026 22:00 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 3,992 | $199.30 | $795,618.37 |
DisclosureSEC source: 0001800668-26-000007 · ownership.xml · nonDerivative · entry 2 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,216 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F2 · balance_after: Includes 43,650 restricted stock units. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 22:00 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 61 | $195.00 | $11,895.00 |
DisclosureSEC source: 0001800668-26-000007 · ownership.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,208 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 20:10 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $18.56 | $0.00 |
DisclosureSEC source: 0001610717-26-000296 · form4.xml · derivative · entry 6 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,600 Underlying: Common Stock · 20,000 shares Expires 2032-02-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 24, 2026. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 20:10 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 300 | $170.32 | $51,096.00 |
DisclosureSEC source: 0001610717-26-000296 · form4.xml · nonDerivative · entry 5 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,269 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 24, 2026. F6 · price: This transaction was executed in multiple trades at prices ranging from $169.81 to $170.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 51,388 restricted stock units. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 20:10 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 5,651 | $169.24 | $956,398.41 |
DisclosureSEC source: 0001610717-26-000296 · form4.xml · nonDerivative · entry 4 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,569 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 24, 2026. F5 · price: This transaction was executed in multiple trades at prices ranging from $168.78 to $169.74. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 51,388 restricted stock units. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 20:10 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 9,496 | $168.20 | $1,597,188.27 |
DisclosureSEC source: 0001610717-26-000296 · form4.xml · nonDerivative · entry 3 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,220 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 24, 2026. F4 · price: This transaction was executed in multiple trades at prices ranging from $167.77 to $168.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 51,388 restricted stock units. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 20:10 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 4,553 | $167.35 | $761,921.79 |
DisclosureSEC source: 0001610717-26-000296 · form4.xml · nonDerivative · entry 2 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,716 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 24, 2026. F3 · price: This transaction was executed in multiple trades at prices ranging from $166.76 to $167.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 51,388 restricted stock units. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 20:10 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 20,000 | $18.56 | $371,200.00 |
DisclosureSEC source: 0001610717-26-000296 · form4.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,269 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 24, 2026. F2 · balance_after: Includes 51,388 restricted stock units. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:10 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,722 | $156.12 | $424,956.46 |
DisclosureSEC source: 0001610717-26-000244 · form4.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,269 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $156.1105 to $156.8251. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: Includes 51,388 RSUs. F4 · balance_after: Includes 479 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 22:55 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,753 | $99.48 | $273,869.54 |
DisclosureSEC source: 0001610717-26-000128 · form4.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,512 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · balance_after: Includes 56,600 RSUs. Read SEC document |
| March 01, 2026 Filed Mar 4, 2026 02:07 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 45,400 | $0.00 Strike: $102.02 | $0.00 |
DisclosureSEC source: 0001610717-26-000079 · form4.xml · derivative · entry 2 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,400 Underlying: Common Stock · 45,400 shares Expires 2036-02-28 F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 01, 2026 Filed Mar 4, 2026 02:07 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 20,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000079 · form4.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,265 F1 · balance_after: Includes 62,538 restricted stock units. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 21:20 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $42.45 | $0.00 |
DisclosureSEC source: 0001610717-26-000012 · form4.xml · derivative · entry 3 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,900 Underlying: Common Stock · 10,000 shares Expires 2031-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 21:20 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 10,000 | $98.00 | $980,000.00 |
DisclosureSEC source: 0001610717-26-000012 · form4.xml · nonDerivative · entry 2 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,065 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024. F2 · balance_after: Includes 42,338 restricted stock units. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 21:20 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 10,000 | $42.45 | $424,500.00 |
DisclosureSEC source: 0001610717-26-000012 · form4.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024. F2 · balance_after: Includes 42,338 restricted stock units. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 21:15 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 3,104 | $77.09 | $239,288.60 |
DisclosureSEC source: 0001610717-25-000420 · form4.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,065 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · balance_after: Includes 175 shares acquired under the Issuer's Employee Stock Purchase Plan on November 30, 2025. F3 · balance_after: Includes 42,338 restricted stock units. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 21:16 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,418 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000404 · form4.xml · derivative · entry 3 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,418 shares Expires 2030-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 21:16 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 5,418 | $74.00 | $400,932.00 |
DisclosureSEC source: 0001610717-25-000404 · form4.xml · nonDerivative · entry 2 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,994 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024. F2 · balance_after: Includes 48,275 restricted stock units. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 21:16 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 5,418 | $17.00 | $92,106.00 |
DisclosureSEC source: 0001610717-25-000404 · form4.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024. F2 · balance_after: Includes 48,275 restricted stock units. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 21:20 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000377 · form4.xml · derivative · entry 3 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,418 Underlying: Common Stock · 10,000 shares Expires 2030-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 21:20 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 10,000 | $64.00 | $640,000.00 |
DisclosureSEC source: 0001610717-25-000377 · form4.xml · nonDerivative · entry 2 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,994 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024. F2 · balance_after: Includes 48,275 restricted stock units. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 21:20 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 10,000 | $17.00 | $170,000.00 |
DisclosureSEC source: 0001610717-25-000377 · form4.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024. F2 · balance_after: Includes 48,275 restricted stock units. Read SEC document |
| September 16, 2025 Filed Sep 18, 2025 20:34 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,320 | $45.82 | $106,313.77 |
DisclosureSEC source: 0001610717-25-000346 · form4.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,994 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · balance_after: Includes 48,275 restricted stock units. Read SEC document |
| September 03, 2025 Filed Sep 4, 2025 23:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,049 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000326 · form4.xml · derivative · entry 10 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,418 Underlying: Common Stock · 2,049 shares Expires 2030-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024. Read SEC document |
| September 03, 2025 Filed Sep 4, 2025 23:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,189 | $0.00 Strike: $4.73 | $0.00 |
DisclosureSEC source: 0001610717-25-000326 · form4.xml · derivative · entry 9 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,189 shares Expires 2029-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024. Read SEC document |
| September 03, 2025 Filed Sep 4, 2025 23:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 5,238 | $40.17 | $210,432.46 |
DisclosureSEC source: 0001610717-25-000326 · form4.xml · nonDerivative · entry 6 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,314 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024. F4 · price: This transaction was executed in multiple trades in prices ranging from $40.01 to $40.32, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 54,213 RSUs. Read SEC document |
| September 03, 2025 Filed Sep 4, 2025 23:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 2,049 | $17.00 | $34,833.00 |
DisclosureSEC source: 0001610717-25-000326 · form4.xml · nonDerivative · entry 5 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,552 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024. F2 · balance_after: Includes 54,213 RSUs. Read SEC document |
| September 03, 2025 Filed Sep 4, 2025 23:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 3,189 | $4.73 | $15,083.97 |
DisclosureSEC source: 0001610717-25-000326 · form4.xml · nonDerivative · entry 4 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,503 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024. F2 · balance_after: Includes 54,213 RSUs. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 23:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,948 | $0.00 Strike: $4.73 | $0.00 |
DisclosureSEC source: 0001610717-25-000326 · form4.xml · derivative · entry 8 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,189 Underlying: Common Stock · 1,948 shares Expires 2029-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 23:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,814 | $0.00 Strike: $2.68 | $0.00 |
DisclosureSEC source: 0001610717-25-000326 · form4.xml · derivative · entry 7 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,814 shares Expires 2028-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 23:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 4,762 | $40.02 | $190,560.00 |
DisclosureSEC source: 0001610717-25-000326 · form4.xml · nonDerivative · entry 3 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,314 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024. F3 · price: This transaction was executed in multiple trades in prices ranging from $40.00 to $40.05, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 54,213 RSUs. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 23:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 1,948 | $4.73 | $9,214.04 |
DisclosureSEC source: 0001610717-25-000326 · form4.xml · nonDerivative · entry 2 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,076 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024. F2 · balance_after: Includes 54,213 RSUs. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 23:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 2,814 | $2.68 | $7,541.52 |
DisclosureSEC source: 0001610717-25-000326 · form4.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024. F2 · balance_after: Includes 54,213 RSUs. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 20:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,170 | $39.83 | $86,431.10 |
DisclosureSEC source: 0001610717-25-000239 · form4.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,314 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · price: This transaction was executed in multiple trades in prices ranging from $39.5913 to $39.8291, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 478 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2025. F4 · balance_after: Includes 54,213 RSUs. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 21:42 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,864 | $39.04 | $72,771.12 |
DisclosureSEC source: 0001610717-25-000079 · form4.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,006 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · balance_after: Includes 60,150 RSUs. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 00:02 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 71,400 | $0.00 Strike: $40.74 | $0.00 |
DisclosureSEC source: 0001610717-25-000055 · form4.xml · derivative · entry 2 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,400 Underlying: Common Stock · 71,400 shares Expires 2035-02-28 F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2025 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 00:02 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 20,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000055 · form4.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,870 F1 · balance_after: Includes 65,276 restricted stock units. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 21:06 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,635 | $45.40 | $119,639.01 |
DisclosureSEC source: 0001610717-24-000543 · form4.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,470 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · balance_after: Includes 173 shares acquired under the Issuer's Employee Stock Purchase Plan on November 30, 2024. F3 · balance_after: Includes 44,876 RSUs. Read SEC document |
| October 11, 2024 Filed Oct 15, 2024 21:30 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.68 | $0.00 |
DisclosureSEC source: 0001610717-24-000507 · form4.xml · derivative · entry 3 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,814 Underlying: Common Stock · 10,000 shares Expires 2028-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person adopted on March 14, 2024. Read SEC document |
| October 11, 2024 Filed Oct 15, 2024 21:30 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 10,000 | $50.30 | $502,979.00 |
DisclosureSEC source: 0001610717-24-000507 · form4.xml · nonDerivative · entry 2 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,932 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person adopted on March 14, 2024. F3 · price: This transaction was executed in multiple trades in prices ranging from $50.00 to $50.78, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 50,000 restricted stock units. Read SEC document |
| October 11, 2024 Filed Oct 15, 2024 21:30 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 10,000 | $2.68 | $26,800.00 |
DisclosureSEC source: 0001610717-24-000507 · form4.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,932 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person adopted on March 14, 2024. F2 · balance_after: Includes 50,000 restricted stock units. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 20:18 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,244 | $44.19 | $99,151.81 |
DisclosureSEC source: 0001610717-24-000489 · form4.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,932 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · balance_after: Includes 50,000 RSUs. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 20:13 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,893 | $37.39 | $70,774.73 |
DisclosureSEC source: 0001610717-24-000351 · form4.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,176 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · price: This transaction was executed in multiple trades in prices ranging from $37.3869 to $37.3887, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 1,110 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2024. F4 · balance_after: Includes 55,126 RSUs. Read SEC document |
| May 03, 2024 Filed May 3, 2024 23:36 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.68 | $0.00 |
DisclosureSEC source: 0001610717-24-000229 · form4.xml · derivative · entry 3 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,814 Underlying: Common Stock · 10,000 shares Expires 2028-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person adopted on March 27, 2023. Read SEC document |
| May 03, 2024 Filed May 3, 2024 23:36 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 10,000 | $40.03 | $400,260.00 |
DisclosureSEC source: 0001610717-24-000229 · form4.xml · nonDerivative · entry 2 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,959 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person adopted on March 27, 2023. F3 · price: This transaction was executed in multiple trades in prices ranging from $40.00 to $40.13, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 60,250 restricted stock units. Read SEC document |
| May 03, 2024 Filed May 3, 2024 23:36 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 10,000 | $2.68 | $26,800.00 |
DisclosureSEC source: 0001610717-24-000229 · form4.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,959 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person adopted on March 27, 2023. F2 · balance_after: Includes 60,250 restricted stock units. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 20:43 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,261 | $31.58 | $39,826.42 |
DisclosureSEC source: 0001610717-24-000170 · form4.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,959 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · shares: Pursuant to an automatic sell-to-cover imposed by the terms of the RSUs award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F3 · balance_after: Includes 60,250 RSUs. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:53 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 92,400 | $0.00 Strike: $29.80 | $0.00 |
DisclosureSEC source: 0001610717-24-000130 · form4.xml · derivative · entry 2 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,400 Underlying: Common Stock · 92,400 shares Expires 2034-02-28 F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2024 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:53 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 26,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000130 · form4.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,220 F1 · balance_after: Includes 63,726 restricted stock units. F2 · balance_after: Includes 404 shares acquired under the Issuer's Employee Stock Purchase Plan on November 30, 2023. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 22:10 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,775 | $25.90 | $45,975.70 |
DisclosureSEC source: 0001610717-23-000416 · form4.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,416 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · shares: Pursuant to an automatic sell-to-cover imposed by the terms of the RSUs award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F3 · price: This transaction was executed in multiple trades in prices ranging from $25.9017 to $25.9385, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4 · balance_after: Includes 37,326 RSUs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.